Sigyn Therapeutics, Inc.
SIGY
$2.76
-$0.99-26.40%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.48% | 35.18% | -23.42% | 40.86% | 2.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.11% | -13.32% | -33.35% | 25.78% | 5.02% |
| Operating Income | 22.11% | 13.32% | 33.35% | -25.78% | -5.02% |
| Income Before Tax | -68.27% | 11.81% | 55.55% | -32.15% | -19.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.27% | 11.81% | 55.55% | -32.15% | -19.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.27% | 11.81% | 55.55% | -32.15% | -19.26% |
| EBIT | 22.11% | 13.32% | 33.35% | -25.78% | -5.02% |
| EBITDA | 21.93% | 13.32% | 33.20% | -25.89% | -5.25% |
| EPS Basic | -29.79% | 32.41% | 65.12% | -15.19% | -4.34% |
| Normalized Basic EPS | -28.23% | 32.41% | 71.18% | -15.18% | 19.01% |
| EPS Diluted | -29.14% | 32.26% | 64.73% | -15.05% | -4.48% |
| Normalized Diluted EPS | -28.23% | 32.41% | 71.18% | -15.18% | 19.01% |
| Average Basic Shares Outstanding | 29.67% | 30.48% | 27.46% | 14.74% | 14.29% |
| Average Diluted Shares Outstanding | 29.67% | 30.48% | 27.46% | 14.74% | 14.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |